Institutional members access full text with Ovid®

Share this article on:

Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohn's disease: P-39.

Sands, BE1; Gasink, C2; Gao, L-L2; Blank, MA2; Johanns, J2; Guzzo, C2; Chiou, C-F2; Sandborn, WJ3; Hanauer, SB4; Targan, S5; Rutgeerts, P6; Ghosh, S7; de Villiers, W8; Panaccione, R9; Greenberg, G10; Schreiber, S11; Lichtiger, S1; Feagan, BG12

Inflammatory Bowel Diseases: December 2011 - Volume 17 - Issue - p S24
Clinical Poster Presentations
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website